English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Bergenbio Asa
Press release submission
| Jun 14, 2019
BERGENBIO ASA: BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy
Trending
+
Technology/Innovation
Patient Daily News Service
| Oct 9, 2025
Babylon Health collapse raises questions about AI claims across industries
Patient Daily
| Oct 9, 2025
Medfluence Advisors Marketing Expert: 'The conversations leading into AAO-HNSF are shaping how ENT practices approach growth and engagement'
Patient Daily
| Oct 9, 2025
AI takes center stage at ASCENT ENT conference, reshaping marketing and operations
+
Pharmaceuticals
Patient Daily
| Oct 8, 2025
American Lung Association launches campaign urging vaccinations against seasonal flu and respiratory illnesses
